Clinical Commander

Back to dossier
heme.thalassemia.core.v1PRODUCTION
heme.thalassemia.core.v1

Thalassaemia (TDT / NTDT / α-thal-HbH / trait — chronic management)

hematologychronicadultpediatricpregnancygeriatricneonatal
Hard-required inputs
0 / 6
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Assign phenotype tier — TDT (β-major / severe HbE-β / α0/α0 Hb Barts hydrops) vs NTDT (β-intermedia / HbH / mild HbE-β) vs trait/carrier; globin type (α vs β); genotype severity (β0/β0 vs non-β0/β0) (TIF 5th ed 2025 PMID 40045934; NTDT 2023 NBK599489)

Inputs
1
Actions
0
Advance rule
Set
Advance when

Phenotype tier + globin type assigned

Patient inputs (11)

HbA2 >3.5% → β-trait; ↑HbF; HbH/HbE bands → α / HbE phenotype (TIF 5th ed 2025)

Pediatric vs adult vs geriatric management; transfusion-initiation criteria; HSCT/gene-therapy timing; weight-based chelation (TIF 5th ed 2025 PMID 40045934)

TDT vs NTDT classification; pre-transfusion Hb target ~9.5–10.5 g/dL; alloimmunisation risk (TIF 5th ed 2025)

β0/β0 vs non-β0/β0 vs HbE/β vs α0/α0 vs HbH (deletional/non-deletional) — defines TDT vs NTDT and disease severity (TIF 5th ed 2025; NTDT 2023 NBK599489)

Hb, MCV, MCH, RBC count, RDW — microcytosis + Mentzer index (MCV/RBC) <13 discriminates trait vs IDA (cross-pivot to heme.iron-deficiency-anemia.core.v1)

Iron-overload trend (transfusional + GI-absorption); chelation threshold; ALSO the anti-pattern guard — normal/raised ferritin in microcytosis argues trait not IDA (TIF 5th ed 2025)

Asplenia → encapsulated-organism prophylaxis + high thrombosis/PHTN risk (TIF NTDT 2023 NBK599489)

Pre-conception chelation washout; switch to deferoxamine if chelation needed; intensified transfusion; thromboprophylaxis; partner screening (TIF 5th ed 2025)

Chronic haemolytic component; aplastic crisis = Hb drop with LOW reticulocytes (parvovirus B19) (TIF 5th ed 2025)

Myocardial iron — T2* <20 ms intensify chelation, <10 ms high HF risk (RR≈160) → combination chelation (Kirk/Pennell Circulation 2009 PMID 19801505; Tanner PMID 17372174)

LIC by MRI R2/R2* — chelation intensity + hepatic-fibrosis/cirrhosis risk (TIF 5th ed 2025)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningiron_cardiomyopathy
    Cardiac T2* <10 ms and/or new heart failure / arrhythmia from myocardial siderosis (RR≈160 for HF vs T2* >10 ms; 47% HF within 1 yr if T2* <6 ms) (Kirk/Pennell Circulation 2009 PMID 19801505)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_splenectomy_sepsis
    Fever in a splenectomised / functionally asplenic thalassaemia patient — overwhelming encapsulated-organism infection until proven otherwise (TIF 5th ed 2025 PMID 40045934)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningdeferiprone_agranulocytosis
    Deferiprone-associated ANC <0.5 ×10⁹/L (agranulocytosis ~1–2%) (TIF 5th ed 2025 PMID 40045934)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereaplastic_crisis_parvovirus
    Acute Hb drop below baseline with LOW reticulocyte count — parvovirus B19 transient red-cell aplasia (TIF 5th ed 2025 PMID 40045934)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverentdt_thrombosis_pulmonary_hypertension
    New venous/arterial thrombosis or pulmonary hypertension in NTDT or post-splenectomy thalassaemia (high prothrombotic state) (TIF NTDT 2023 NBK599489)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepregnancy_intensified_transfusion
    Pregnancy in thalassaemia with anaemia / fetal growth restriction requiring intensified or initiated regular transfusion + chelation washout (TIF 5th ed 2025 PMID 40045934)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

MONITORINGoptionalDrives monitoring threshold
Loading…

Recommended regimen

Iron chelation (compartment- and cardiac-T2*-directed)
axis: thalassemia_iron_chelation
Selected axis "Iron chelation (compartment- and cardiac-T2*-directed)" by default fallback (first axis)
  • deferasirox
    first line
    oral_iron_chelator
    14 mg/kg/day (film-coated tablet); titrate 7–28 mg/kg • PO • once daily (max: max 28 mg/kg/day)
    triggers: serum_ferritin_persistently_>1000, LIC_elevated, on_regular_transfusion
    First-line PO chelator; titrate by ferritin/LIC trend. Boxed warning: renal/hepatic failure, GI haemorrhage — monitor eGFR + LFT + GI symptoms (TIF 5th ed 2025 PMID 40045934)
    rxcui 614373
  • deferoxamine
    second line
    parenteral_iron_chelator
    20–40 mg/kg/day SC over 8–12 h; up to 50–60 mg/kg/day IV (intensive) for siderotic cardiomyopathy • SC • 5–7 nights/week (continuous IV if cardiac decompensation)
    triggers: pregnancy, deferasirox_intolerance, siderotic_cardiomyopathy_intensive, combination_for_cardiac_T2*_<10ms
    Pregnancy-preferred chelator; 24-h IV for iron cardiomyopathy; backbone of DFP+DFO combination (Tanner Circulation 2007 PMID 17372174)
    rxcui 3131
  • deferiprone
    add on
    oral_iron_chelator
    75 mg/kg/day divided TID (up to 99 mg/kg/day) • PO • three times daily (max: max 99 mg/kg/day)
    triggers: cardiac_T2*_<20ms, cardiac_T2*_<10ms_combination_with_deferoxamine, inadequate_cardiac_iron_clearance_on_monotherapy
    Superior myocardial iron clearance; combination with deferoxamine for cardiac T2* <10 ms (Tanner PMID 17372174). MANDATORY weekly ANC — agranulocytosis ~1–2% (TIF 5th ed 2025)
    rxcui 11645
  • folic acid
    add on
    vitamin
    5 mg • PO • once daily
    triggers: NTDT_increased_erythropoietic_demand, haemolytic_component, pregnancy
    Supports increased erythropoietic folate demand in chronic haemolysis / ineffective erythropoiesis (TIF NTDT 2023 NBK599489)
    rxcui 4511

outpatient playbook — drug actions (7)

  1. 1. regular RBC transfusion (TDT)
    Phenotype-matched pRBC to pre-transfusion Hb ~9.5–10.5 g/dL • IV • q2–5 weeks
    trigger: TDT phenotype (β-major / severe HbE-β / α0/α0)
    Suppress ineffective erythropoiesis/EMH (TIF 5th ed 2025)
  2. 2. deferasirox
    rxcui 614373
    14 mg/kg/day PO, titrate 7–28 mg/kg • PO • once daily
    trigger: Ferritin persistently >1000 or LIC elevated
    First-line PO chelation (TIF 5th ed 2025)
  3. 3. deferiprone + deferoxamine combination
    rxcui 11645
    DFP 75–99 mg/kg/day PO TID + DFO 30–50 mg/kg/day SC/IV • PO+SC • daily
    trigger: Cardiac T2* <10 ms (high HF risk)
    Combination clears myocardial iron (Tanner Circulation 2007 PMID 17372174)
  4. 4. luspatercept
    rxcui 2262544
    1.0–1.25 mg/kg SC • SC • every 3 weeks
    trigger: High transfusion burden (TDT) or symptomatic NTDT anaemia
    BELIEVE NEJM 2020 PMID 32212518; BEYOND PMID 36007538
  5. 5. hydroxyurea (NTDT)
    rxcui 5552
    10–20 mg/kg/day PO • PO • once daily
    trigger: NTDT β-intermedia / HbE-β with anaemia or EMH
    HbF induction (TIF NTDT 2023 NBK599489)
  6. 6. gene therapy / HSCT referral
    rxcui 2671667
    beti-cel (Zynteglo, RxCUI 2610349) or exa-cel (Casgevy, RxCUI 2671667) or matched-sib HSCT per protocol • IV cellular • one-time
    trigger: TDT, transplant-eligible, no/with donor
    Curative — PMIDs 34891223 / 39527960 / 38657265 (TIF 5th ed 2025)
  7. 7. folic acid + calcium + vitamin D
    rxcui 4511
    Folic acid 5 mg + Ca 500–1000 mg + cholecalciferol 800–2000 IU • PO • daily
    trigger: Haemolytic demand / thalassaemic osteoporosis
    Erythropoietic + bone-health adjuncts (TIF 5th ed 2025)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Microcytic hypochromic anaemia on CBC — discriminate thalassaemia trait vs IDA (TIF 5th ed 2025 PMID 40045934); Known thalassaemia on problem list — comprehensive clinic visit (TIF 5th ed 2025); Abnormal Hb electrophoresis/HPLC (↑HbA2 / ↑HbF / HbH / HbE) (TIF 5th ed 2025).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Thalassaemia (TDT / NTDT / α-thal-HbH / trait — chronic management)** (heme.thalassemia.core.v1).
Phenotype framing: Terminal phenotype: β-major / severe HbE-β (TDT) · β-intermedia / HbH / mild HbE-β (NTDT) · α0/α0 Hb Barts hydrops fetalis · α- or β-thalassaemia trait. Discriminate from IDA (Mentzer >13, low ferritin, high RDW → heme.iron-deficiency-anemia.core.v1), anaemia of chronic disease, sideroblastic, lead, and HbS/β compound (sickling phenotype → heme.sickle-cell.core.v1) (TIF 5th ed 2025)
Scope: Assign phenotype tier — TDT (β-major / severe HbE-β / α0/α0 Hb Barts hydrops) vs NTDT (β-intermedia / HbH / mild HbE-β) vs trait/carrier; globin type (α vs β); genotype severity (β0/β0 vs non-β0/β0) (TIF 5th ed 2025 PMID 40045934; NTDT 2023 NBK599489)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Iron chelation (compartment- and cardiac-T2*-directed)**.
1. deferasirox 14 mg/kg/day (film-coated tablet); titrate 7–28 mg/kg PO once daily (oral_iron_chelator, first line) — First-line PO chelator; titrate by ferritin/LIC trend. Boxed warning: renal/hepatic failure, GI haemorrhage — monitor eGFR + LFT + GI symptoms (TIF 5th ed 2025 PMID 40045934)
2. deferoxamine 20–40 mg/kg/day SC over 8–12 h; up to 50–60 mg/kg/day IV (intensive) for siderotic cardiomyopathy SC 5–7 nights/week (continuous IV if cardiac decompensation) (parenteral_iron_chelator, second line) — Pregnancy-preferred chelator; 24-h IV for iron cardiomyopathy; backbone of DFP+DFO combination (Tanner Circulation 2007 PMID 17372174)
3. deferiprone 75 mg/kg/day divided TID (up to 99 mg/kg/day) PO three times daily (oral_iron_chelator, add on) — Superior myocardial iron clearance; combination with deferoxamine for cardiac T2* <10 ms (Tanner PMID 17372174). MANDATORY weekly ANC — agranulocytosis ~1–2% (TIF 5th ed 2025)
4. folic acid 5 mg PO once daily (vitamin, add on) — Supports increased erythropoietic folate demand in chronic haemolysis / ineffective erythropoiesis (TIF NTDT 2023 NBK599489)

Setting playbook (outpatient) — Comprehensive thalassaemia clinic — phenotype-appropriate transfusion, iron-overload surveillance + chelation, disease-modifying / curative pathway, complication screening, genetic counselling (TIF 5th ed 2025 PMID 40045934)
5. regular RBC transfusion (TDT) Phenotype-matched pRBC to pre-transfusion Hb ~9.5–10.5 g/dL IV q2–5 weeks — TDT phenotype (β-major / severe HbE-β / α0/α0) (Suppress ineffective erythropoiesis/EMH (TIF 5th ed 2025))
6. deferasirox 14 mg/kg/day PO, titrate 7–28 mg/kg PO once daily — Ferritin persistently >1000 or LIC elevated (First-line PO chelation (TIF 5th ed 2025))
7. deferiprone + deferoxamine combination DFP 75–99 mg/kg/day PO TID + DFO 30–50 mg/kg/day SC/IV PO+SC daily — Cardiac T2* <10 ms (high HF risk) (Combination clears myocardial iron (Tanner Circulation 2007 PMID 17372174))
8. luspatercept 1.0–1.25 mg/kg SC SC every 3 weeks — High transfusion burden (TDT) or symptomatic NTDT anaemia (BELIEVE NEJM 2020 PMID 32212518; BEYOND PMID 36007538)
9. hydroxyurea (NTDT) 10–20 mg/kg/day PO PO once daily — NTDT β-intermedia / HbE-β with anaemia or EMH (HbF induction (TIF NTDT 2023 NBK599489))
10. gene therapy / HSCT referral beti-cel (Zynteglo, RxCUI 2610349) or exa-cel (Casgevy, RxCUI 2671667) or matched-sib HSCT per protocol IV cellular one-time — TDT, transplant-eligible, no/with donor (Curative — PMIDs 34891223 / 39527960 / 38657265 (TIF 5th ed 2025))
11. folic acid + calcium + vitamin D Folic acid 5 mg + Ca 500–1000 mg + cholecalciferol 800–2000 IU PO daily — Haemolytic demand / thalassaemic osteoporosis (Erythropoietic + bone-health adjuncts (TIF 5th ed 2025))

Non-pharmacologic actions:
- Pre-splenectomy PCV20 + MenACWY/B + Hib vaccination if splenectomy planned (TIF 5th ed 2025)
- Genetic counselling + partner testing + prenatal/PGT options (TIF 5th ed 2025)
- Pregnancy / pre-conception planning with chelation washout (TIF 5th ed 2025)
- Transition pediatric→adult care plan (TIF 5th ed 2025)
- Education: NO over-the-counter iron in trait/NTDT; avoid iron-fortified supplements (TIF 5th ed 2025)

AVOID / contraindication checks:
- Deferiprone WEEKLY ANC monitoring — stop and treat if ANC <0.5 (agranulocytosis) (TIF 5th ed 2025 PMID 40045934)
- Deferasirox renal + hepatic + GI ulcer boxed warning — monitor eGFR (CKD EPI 2021) + LFT + GI bleeding; suspend if rising creatinine (TIF 5th ed 2025)
- Chelation washout before conception — switch oral chelators off; use deferoxamine only if chelation essential in pregnancy (TIF 5th ed 2025)
- Cardiac T2* <10 ms → escalate to combination DFP+DFO + cardiology, do not continue monotherapy (Tanner Circulation 2007 PMID 17372174; Kirk/Pennell PMID 19801505)

Monitoring

Regimen monitoring:
- Serum ferritin q3 months (TIF 5th ed 2025)
- LIC by MRI R2/R2* annually (TIF 5th ed 2025)
- Cardiac T2* annually; more often if <20 ms (Kirk/Pennell PMID 19801505)
- Deferiprone: ANC weekly (agranulocytosis) (TIF 5th ed 2025)
- Deferasirox: eGFR (CKD-EPI 2021) + LFT monthly initially then q3m (TIF 5th ed 2025)

Setting (outpatient) monitoring:
- Ferritin q3m; LIC + cardiac T2* annually (TIF 5th ed 2025; Kirk/Pennell PMID 19801505)
- Deferiprone ANC weekly; deferasirox eGFR + LFT (TIF 5th ed 2025)
- Annual endocrine + bone densitometry + cardiac + hepatic (TIF 5th ed 2025)
- Alloantibody screen each transfusion (TIF 5th ed 2025)

Follow-up plan: Annual endocrinopathy screen — hypogonadism, growth failure, diabetes, hypothyroidism, hypoparathyroidism, osteoporosis (bone densitometry; calcium + vitamin D); cardiac + hepatic surveillance (HCC screening if cirrhotic — route gi.cirrhosis.core.v1); fertility / pregnancy planning + pre-conception chelation washout; vaccination + lifelong penicillin if splenectomised; transition pediatric→adult care; partner + family genetic counselling, prenatal/PGT options (TIF 5th ed 2025; NTDT 2023 NBK599489)
- Close-out criterion: Complication-surveillance + counselling plan documented

Monitoring phase: Pre-transfusion Hb each visit (target ~9.5–10.5 in TDT); ferritin q3 months; LIC + cardiac T2* annually (more often if T2* <20 ms); ANC WEEKLY on deferiprone (agranulocytosis); renal (eGFR CKD-EPI 2021) + hepatic + GI on deferasirox; alloantibody screen each transfusion episode; growth/pubertal staging in children; LFT trend for hepatic siderosis (TIF 5th ed 2025; Tanner PMID 17372174)

Disposition

Current setting: outpatient — Comprehensive thalassaemia clinic — phenotype-appropriate transfusion, iron-overload surveillance + chelation, disease-modifying / curative pathway, complication screening, genetic counselling (TIF 5th ed 2025 PMID 40045934)

Disposition criteria:
- Continue tier-appropriate regimen if iron burden and complications stable (TIF 5th ed 2025)
- Refer transplant/gene-therapy centre if TDT and eligible (PMIDs 34891223 / 38657265)
- Refer cardiology / endocrinology / hepatology / obstetric haematology / clinical genetics as triggered (TIF 5th ed 2025)

Escalation triggers (move to higher acuity):
- Cardiac T2* <10 ms / new HF symptoms → cardiology + intensive combination chelation + admit (Kirk/Pennell PMID 19801505)
- Acute Hb drop with low reticulocytes → aplastic crisis (parvovirus) → transfusion + admit (TIF 5th ed 2025)
- Fever in splenectomised patient → ED, treat as encapsulated-organism sepsis (TIF 5th ed 2025)
- New thrombosis / pulmonary hypertension in NTDT → ED + anticoagulation assessment (TIF NTDT 2023 NBK599489)
- Deferiprone ANC <0.5 → STOP deferiprone, urgent assessment (TIF 5th ed 2025)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Cardiac T2* <10 ms and/or new heart failure / arrhythmia from myocardial siderosis (RR≈160 for HF vs T2* >10 ms; 47% HF within 1 yr if T2* <6 ms) (Kirk/Pennell Circulation 2009 PMID 19801505)
- [LIFE_THREATENING] Fever in a splenectomised / functionally asplenic thalassaemia patient — overwhelming encapsulated-organism infection until proven otherwise (TIF 5th ed 2025 PMID 40045934)
- [LIFE_THREATENING] Deferiprone-associated ANC <0.5 ×10⁹/L (agranulocytosis ~1–2%) (TIF 5th ed 2025 PMID 40045934)

Citations

- TIF Guidelines for the Management of Transfusion-Dependent β-Thalassaemia, 5th edition 2025 (Musallam/Taher HemaSphere, PMID 40045934) + TIF NTDT 3rd edition 2023 (NBK599489) + BELIEVE/BEYOND luspatercept + beti-cel HGB-207/212 + exa-cel CLIMB THAL-111 + cardiac-T2* (Kirk/Pennell) + combined chelation (Tanner) [PMID:40045934](https://pubmed.ncbi.nlm.nih.gov/40045934/)
- Cited evidence (PMID 32212518) [PMID:32212518](https://pubmed.ncbi.nlm.nih.gov/32212518/)
- Cited evidence (PMID 36007538) [PMID:36007538](https://pubmed.ncbi.nlm.nih.gov/36007538/)
- Cited evidence (PMID 34891223) [PMID:34891223](https://pubmed.ncbi.nlm.nih.gov/34891223/)
- Cited evidence (PMID 39527960) [PMID:39527960](https://pubmed.ncbi.nlm.nih.gov/39527960/)

Last reconciled with current guidelines: 2026-05-16.
References
  • TIF Guidelines for the Management of Transfusion-Dependent β-Thalassaemia, 5th edition 2025 (Musallam/Taher HemaSphere, PMID 40045934) + TIF NTDT 3rd edition 2023 (NBK599489) + BELIEVE/BEYOND luspatercept + beti-cel HGB-207/212 + exa-cel CLIMB THAL-111 + cardiac-T2* (Kirk/Pennell) + combined chelation (Tanner) — PMID:40045934
  • Cited evidence (PMID 32212518) — PMID:32212518
  • Cited evidence (PMID 36007538) — PMID:36007538
  • Cited evidence (PMID 34891223) — PMID:34891223
  • Cited evidence (PMID 39527960) — PMID:39527960